此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Recovery After Critical Covid-19 Infection (RECOVID)

2021年4月27日 更新者:Johanna Hastbacka、University of Helsinki
The study focuses on the recovery of respiratory, cardiovascular and neurological/neuropsychological recovery after intensive care treatment for covid-19. The results will be compared with those obtained from patients treated in the regular wards for covid-19, persons with home treated covid-19 and non-covid controls.

研究概览

地位

邀请报名

条件

详细说明

Eligible patients who have been treated in the intensive care units of Helsinki University Hospital are invited to participate. Controls are recruited from follow-up clinics, and with announcements in media and websites.

The participants receive an invitation to a follow-up clinic where their experiences from the ICU treatment and recovery will be discussed. The investigators will perform neuropsychologic testing (6 months post-discharge), a telephone interview (3 months) and send written questionnaires (3, 6 and 24 months) to the participants. The participants will undergo MRI imaging of the brain and laboratory tests will be taken. The olfactory function will be tested at a follow-up clinic. Data on the patients´ respiratory function from clinical spirometry and diffusion capacity testing 3 and 6 months after discharge are collected. The patients will perform a 6 min walk test.

Data on coagulation laboratory values will be registered from acute phase and 6 months after discharge. The investigators will also analyse ApoE alleles, neurofilament light and NAD-metabolites and study their correlation with neuropsychologic findings and long term symptoms (up to 5 years after hospital discharge).

Participants will also undergo magnetic resonance imaging of the heart at 6-12 months after the hospital discharge, and laboratory samples, a symptom questionnaire and electrocardiogram are collected. Inflammatory parameters and variables associated with regulating inflammation and coagulation will be analysed.

Clinical data from the acute and post-acute phase and demographic data are collected from the patient data management systems.

The target patient number is 75 intensive care treated patients and 50 control persons in each three control group.

研究类型

观察性的

注册 (预期的)

250

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Capital Province Of Finland
      • Helsinki、Capital Province Of Finland、芬兰、00290
        • Helsinki University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 100年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients who are recovering from critical covid-infection and controls that are either patients recovering from a hospital regular ward treated for covid or covid that has not required hospitalisation. Non-covid controls are age and sex-matched persons (matched to ICU treated group of participants) with no covid-19 in history.

描述

Inclusion Criteria:

  • Age 18-100
  • Positive PCR for Sars-CoV-2 (except non-covid controls, who must be negative)
  • Native language Finnish or Swedish
  • Informed consent to study to study participation

Exclusion Criteria:

  • Age under 18
  • Pregnant or lactating
  • Major neurologic diagnosis (TBI, dementia, stroke, Parkinson´s disease before covid-19)
  • Substantially impaired hearing or vision
  • Developmental disability.
  • No consent to study participation
  • Contraindication to MR imaging (such as cardiac pacemaker, allergy to contrast)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Patients: ICU treated covid-19 patients
Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires
Control group 1, covid-19 patients treated in the regular wards
As above, without 6 minute walk test or routine chest x-ray
Control group 2, persons with covid-19 without hospitalization
As above, but without respiratory testing
Control group 3, non-covid controls
As control group 2

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cognitive function 6 months after hospital discharge
大体时间:6 months after hospital discharge
Global score calculated from three domains: memory, executive functions and attention.Memory: WMS-III Word list delayed recall + WMS-III Logical memory delayed recall + Rey Complex Figure, delayed recall Executive: TMB (time, reversed) + Stroop interference (time, reversed) + FAB score Attention: WAIS-IV Coding + CPT (correct items) + Stroop naming (time, reversed) The global score will be compared with controls and age matched national references
6 months after hospital discharge
Diffusion capacity 6 months after hospital discharge
大体时间:6 months after hospital discharge
Diffusion capacity DLCO results (percentage of predicted) 6 months after ICU treatment for covid-19
6 months after hospital discharge
Incidence of post myocarditis findings in MRI of the heart
大体时间:6-12 months after hospital discharge
Incidence of findings in cardiac MRI indicating previous myocarditis in each group
6-12 months after hospital discharge
Six minute walk test distance
大体时间:6 months after hospital discharge
The distance in meters walked by ICU treated patients in 6 minutes in controlled test environment
6 months after hospital discharge
Restriction in lung function tests
大体时间:6 months after hospital discharge
Restriction in lung function parameters vital capacity and forced vital capacity (z-scores) in measured by spirometry
6 months after hospital discharge
Cerebral microbleeds
大体时间:6 months after hospital discharge
Number and anatomical distribution of cerebral microbleeds in MRI imaging of the brain
6 months after hospital discharge
Plasma matrix metalloproteinases -8, -9 and TIMP-1 6 months after hospital discharge
大体时间:6 moths after hospital discharge
Plasma matrix metalloproteinases -8, -9 and TIMP-1 levels in ng/mL 6 months after hospital discharge
6 moths after hospital discharge
Plasma neurofilament level and its correlation with global score in neuropsychological test battery
大体时间:6 months after hospital discharge
Plasma neurofilament level and its correlation with global score in neuropsychological test battery
6 months after hospital discharge

次要结果测量

结果测量
措施说明
大体时间
Correlation ApoE 4 alleles with disease severity
大体时间:6 months post-covid
Laboratory analysis of ApoE alleles and comparison of their frequencies among groups
6 months post-covid
Correlation of cerebral microbleeds with neuropsychological global score
大体时间:6 moths after hospital discharge
Correlation of type and location of cerebral microbleeds with neuropsychological global score
6 moths after hospital discharge
Association of the incidence of cerebral microbleeds with findings in cardiac MRI
大体时间:6-12 months after hospital discharge
Association of the incidence of cerebral microbleeds with findings in cardiac MRI
6-12 months after hospital discharge
Correlation of plasma neurofilament with cerebral microbleeds
大体时间:6 months after hospital discharge
Correlation of plasma neurofilament with cerebral microbleeds in brain MR imaging
6 months after hospital discharge
Correlation of 6 minute walk test heart rate variables with cardiac function
大体时间:6-12 months after hospital discharge
Correlation of heart rate in rest, exercise and 5 minutes after exercise with cardiac output measured in heart MRI
6-12 months after hospital discharge
Correlation of matrix metalloproteinase 9 with diffusion capacity
大体时间:6 months after hospital discharge
Correlation of matrix metalloproteinase 9 (ng/mL) with lung diffusion capacity z-score
6 months after hospital discharge

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年8月1日

初级完成 (预期的)

2024年7月25日

研究完成 (预期的)

2024年7月25日

研究注册日期

首次提交

2021年2月9日

首先提交符合 QC 标准的

2021年4月27日

首次发布 (实际的)

2021年4月29日

研究记录更新

最后更新发布 (实际的)

2021年4月29日

上次提交的符合 QC 标准的更新

2021年4月27日

最后验证

2021年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

新冠肺炎的临床试验

3
订阅